Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel.

BACKGROUND Mistrafficking of CFTR protein caused by F508del, the most frequent mutation in cystic fibrosis (CF), can be corrected by cell incubation at low temperature, an effect that may be mediated by altered expression of proteostasis genes. METHODS To identify small molecules mimicking low temperature, we compared gene expression profiles of cells kept at 27°C with those previously generated from more than 1300 compounds. The resulting candidates were tested with a functional assay on a bronchial epithelial cell line. RESULTS We found that anti-inflammatory glucocorticoids, such as mometasone, budesonide, and fluticasone, increased mutant CFTR function. However, this activity was not confirmed in primary bronchial epithelial cells. Actually, glucocorticoids enhanced Na(+) absorption, an effect that could further impair mucociliary clearance in CF airways. CONCLUSIONS Our results suggest that rescue of F508del-CFTR by low temperature cannot be easily mimicked by small molecules and that compounds with closer transcriptional and functional effects need to be found.

[1]  M. Amaral,et al.  Most F508del-CFTR Is Targeted to Degradation at an Early Folding Checkpoint and Independently of Calnexin , 2005, Molecular and Cellular Biology.

[2]  M. Welsh,et al.  Reduced Airway Surface pH Impairs Bacterial Killing in the Porcine Cystic Fibrosis Lung , 2012, Nature.

[3]  M. Amaral,et al.  HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. , 2013, ACS chemical biology.

[4]  Piotr Zielenkiewicz,et al.  Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain , 2013, EMBO molecular medicine.

[5]  D. Hill,et al.  A Periciliary Brush Promotes the Lung Health by Separating the Mucus Layer from Airway Epithelia , 2012, Science.

[6]  John A. Tallarico,et al.  Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.

[7]  A S Verkman,et al.  CFTR: folding, misfolding and correcting the ΔF508 conformational defect. , 2012, Trends in molecular medicine.

[8]  Alberto Luini,et al.  Ouabain Mimics Low Temperature Rescue of F508del-CFTR in Cystic Fibrosis Epithelial Cells , 2012, Front. Pharmacol..

[9]  L. Cebotaru,et al.  Dexamethasone Regulates CFTR Expression in Calu-3 Cells with the Involvement of Chaperones HSP70 and HSP90 , 2012, PloS one.

[10]  Milan Macek,et al.  Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening , 2002, Human mutation.

[11]  D. Borowitz,et al.  Gastrointestinal complications of cystic fibrosis. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  L. Galietta.  Managing the Underlying Cause of Cystic Fibrosis: A Future Role for Potentiators and Correctors , 2013, Pediatric Drugs.

[13]  Jinglan Zhou,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[14]  C. R. Kaffer,et al.  Inhibition of myogenesis by ouabain: Effect on protein synthesis , 2000, In Vitro Cellular & Developmental Biology - Animal.

[15]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[16]  E. Hoffman,et al.  Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis , 2014, Science.

[17]  D. Madden,et al.  Serum- and Glucocorticoid-induced Protein Kinase 1 (SGK1) Increases the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in Airway Epithelial Cells by Phosphorylating Shank2E Protein* , 2014, The Journal of Biological Chemistry.

[18]  Harvey B Pollard,et al.  Rescue of ΔF508-CFTR by the SGK1/Nedd4-2 Signaling Pathway* , 2009, The Journal of Biological Chemistry.

[19]  L. Suaud,et al.  Regulation of endogenous ENaC functional expression by CFTR and ΔF508-CFTR in airway epithelial cells. , 2011, American journal of physiology. Lung cellular and molecular physiology.

[20]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[21]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Quinton,et al.  Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. , 2009, The Journal of clinical investigation.

[23]  N. Pedemonte,et al.  Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. , 2011, American journal of physiology. Cell physiology.

[24]  Jason C. Young,et al.  Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane , 2010, Science.

[25]  Matthew P. Anderson,et al.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive , 1992, Nature.

[26]  John R Yates,et al.  Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. , 2010, Nature chemical biology.

[27]  John Geibel,et al.  Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells , 2002, Nature Medicine.

[28]  J. Sato,et al.  Serum and Glucocorticoid-Inducible Kinase1 Increases Plasma Membrane wt-CFTR in Human Airway Epithelial Cells by Inhibiting Its Endocytic Retrieval , 2014, PloS one.

[29]  M. Johansson,et al.  Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype , 2012, The Journal of experimental medicine.

[30]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[31]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[32]  M. Ramírez-Ortega,et al.  Proliferation and apoptosis of HeLa cells induced by in vitro stimulation with digitalis. , 2006, European journal of pharmacology.

[33]  M. Proesmans,et al.  What’s new in cystic fibrosis? From treating symptoms to correction of the basic defect , 2008, European Journal of Pediatrics.

[34]  K. Winnicka,et al.  Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. , 2006, Biological & pharmaceutical bulletin.

[35]  R. Ravazzolo,et al.  Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia , 2012, The Journal of physiology.

[36]  G. Lukács,et al.  Mechanism-based corrector combination restores ΔF508-CFTR folding and function , 2013, Nature Chemical Biology.

[37]  Diego di Bernardo,et al.  Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis , 2014, Bioinform..

[38]  S. Randell,et al.  Coordinated clearance of periciliary liquid and mucus from airway surfaces. , 1998, The Journal of clinical investigation.

[39]  F. van Goor,et al.  Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[40]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.